Immunotherapy has revolutionized the treatment of patients with cancer. However,
promoting antitumour immunity in patients with tumours that are resistant to these therapies …

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths
worldwide and is increasing in incidence. Local ablative therapy plays a leading role in HCC …

Background: Primary liver cancer, around 90% are hepatocellular carcinoma in China, is the
fourth most common malignancy and the second leading cause of tumor-related death …

Standard for diagnosis and treatment of primary liver cancer (2022 edition) 中文|English ISSN
1001-5256 (Print) ISSN 2097-3497 (Online) CN 22-1108/R Home About Journal 1.Journal …

Background: Primary liver cancer, of which around 75–85% is hepatocellular carcinoma in
China, is the fourth most common malignancy and the second leading cause of tumor …

Primary liver cancer has become the second most fatal cancer in the world, and its five-year
survival rate is only 10%. Most patients are in the middle and advanced stages at the time of …

Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide, but a major
proportion of patients are not appropriate candidates for surgical resection or …

Hepatocellular carcinoma (HCC) is the leading cause of cancer-related death worldwide.
Local ablation, such as radiofrequency ablation, microwave ablation, cryoablation and …

Objective The purpose of this article is to discuss the use, comparative efficacy, and
research progress of radiofrequency ablation (RFA), alone or in combination with other …

Recent studies have shown that miR-494-3p is oncogene and has a central role in many
solid tumors; however, the role of miR-494-3p in the progression and prognosis of …